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Abstract 
------------- 
Purpose: to quantify the error in evaluating recovery from acute kidney injury 
(AKI) with estimated GFR (eGFR) in relation to ICU stay. 
Methods:  secondary analysis performed on the database of the EPaNIC trial. In a 
cohort of patients who developed AKI during ICU stay we compared eGFR with 
measured creatinine clearance (Clcr) at ICU discharge. Recovery of kidney 
function was assessed by comparison with baseline eGFR and the accuracy of 
eGFR to detect “potential CKD status” defined by Clcr was quantified. The same 
analysis was performed in subgroups with different ICU stay. Multivariate 
regression was performed to determine independent predictors of the eGFR-Clcr 
difference. 
Results: 757 patients were included. The bias (limits of agreement (LOA)) between 
eGFR and Clcr at ICU discharge related to ICU stay, increasing from +1.3 (-
37.4/+40) ml/min/1.73m
2
 in patients with short stay to +34.7 (-54.4/+123.8) 
ml/min/1.73m
2
 in patients with ICU stay of more than 14 days. This resulted in a 
significantly different incidence of complete recovery with the two evaluation 
methods and reduced sensitivity to detect “potential CKD status” with eGFR in 
patients with prolonged ICU stay. Independent predictors of the bias included 
creatinine excretion on the last day in ICU, baseline eGFR, ICU stay, gender and 
age. 
Conclusion: Compared to Clcr, discharge eGFR results in overestimation of renal 
recovery in patients with prolonged ICU stay and in reduced accuracy of “CKD 
staging”. Since age, gender and race do not change during ICU stay the same 
conclusion can be drawn with regard to plasma creatinine. 
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Take home message: in patients with prolonged ICU stay recovery of AKI is 
significantly overestimated when assessed with eGFR  
 
140-character tweet: using discharge eGFR instead of creatinine clearance results 
in overestimation of recovery from AKI in patients with prolonged ICU stay  
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Introduction    
--------------- 
Acute kidney injury (AKI) is a frequent and severe complication in ICU patients. 
Over the past ten years consensus has been reached on how to define this 
syndrome, based on urine output and changes in serum creatinine compared with 
baseline [1]. Baseline creatinine reflects baseline glomerular filtration rate (GFR), 
the most commonly used parameter to describe kidney function. GFR can be 
measured as the clearance of endogenous (creatinine) or exogenous (inulin, 
51
Cr-
EDTA, iothalamate, iohexate) markers or can be estimated by equations that 
besides serum creatinine include anthropometric characteristics that account for 
differences in creatinine generation such as age, gender and race [2,3]. The most 
popular equations are the MDRD [4] and the CKD-EPI equation [5], which have 
been developed in patients with stable chronic kidney disease.                  
 
In an important proportion of patients with AKI kidney function will recover. A 
correct estimation of renal recovery has prognostic implications and is important 
for planning post discharge renal care [6-8]. The optimal method for determining 
recovery from AKI would be to compare discharge GFR with baseline GFR, both 
measured with a golden standard such as inulin, radioisotopes or iodinated contrast 
agents [2,3]. Because this is cumbersome in clinical practice recovery is usually 
measured by comparing discharge serum creatinine or eGFR with baseline 
creatinine or eGFR [9-12].  
 
eGFR equations are not validated at high GFR levels [13,14] and do not take into 
account deviations from population anthropometric measurements. Small studies in 
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critically ill patients, concentrating on the diagnosis of AKI and using creatinine 
clearance (Clcr) as the reference method, have shown poor correlations with eGFR 
equations [15-19]. Prolonged critical illness is characterized by important muscle 
wasting (sarcopenia) [20,21]. Reduced creatinine generation (a reflection of muscle 
mass) has also been demonstrated in patients with AKI [22]. In these wasted 
patients the use of discharge eGFR is expected to result in overestimation of GFR 
and thus of renal recovery. Similar restrictions can be made with regard to the use 
of serum creatinine.    
 
The aim of this study was to quantify the risk of potential misclassification of renal 
recovery induced by using an eGFR-based assessment (derived from discharge 
creatinine). For this purpose we first compared the eGFR at ICU discharge with 
measured Clcr based on 24h urine collection. Subsequently we assessed the 
difference in the incidence of recovery with these two parameters by comparing 
both with baseline eGFR and determined the accuracy of discharge eGFR to detect 
discharge “CKD staging” based on Clcr. We further hypothesized that the 
difference between the two methods of assessing recovery relates to ICU stay and 
the degree of muscle wasting.      
 
Methods 
------------- 
Patients 
This analysis was performed on the database of the EPaNIC trial [23] comparing 
two nutritional strategies in a heterogeneous population of 4640 adult ICU patients 
that were included between August 2007 and November 2010. Written informed 
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consent was obtained from all patients or their designated representatives. The 
protocol was approved by the institutional review board of the participating centers 
and by the Belgian authorities. The incidence of AKI was determined in the study 
population after exclusion of patients with end stage renal disease (ESRD), kidney 
transplantation or incomplete data. For this analysis we included all patients who 
developed AKI during their ICU stay but excluded those who died in ICU, those 
who were still on renal replacement therapy (RRT) at ICU discharge and those for 
whom Clcr on the last day in ICU was not available.   
 
Definition of AKI and measurement of renal recovery 
AKI was classified according to the KDIGO criteria and defined by the maximal 
stage during ICU stay (AKImax). Since hourly urine output was not available in the 
database we only used the creatinine criteria [1]. For baseline serum creatinine we 
used the lowest creatinine in 3 months before ICU admission (elective admission) 
or the lowest creatinine from 3 months to 1 week before ICU admission 
(emergency admission). Serum creatinine was searched from the hospital database 
or manually retrieved by searching documents from referring hospitals/physicians. 
In case of missing values a baseline creatinine was calculated from the 
Modification of Diet in Renal Disease formula using an eGFR of 75ml/min/1.73m
2
 
[4].  
 
Two methods for estimating kidney function at ICU discharge were compared: the 
eGFR (MDRD equation) based on the last serum creatinine in the ICU: 
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eGFR = 175 x (Pcr)
-1.154
 x (age, yr)
-0.203
x 1.212 (if black) x  0.742 (if female) 
ml/min/1.73m
2
 
 
and the Clcr measured on a 24h urine collection on the last complete day in ICU. 
The Clcr measurement was part of routine care. Urine was collected over a 24h 
period and a mixed sample sent for analysis. For serum creatinine we used the 
mean of the measurement at the start and the end of the collection. All creatinine 
measurements were performed with an IDMS-traceable Jaffé method. Clcr was 
standardized to body surface area (BSA) for comparison with eGFR:  
 
Clcr = (urine creatinine x urine output x 1.73)/(serum creatinine x 1440 x BSA) 
ml/min/1.73m
2
 
 
Since muscle mass was assumed to be an important determinant of the eGFR-Clcr 
difference we measured creatinine excretion (reflecting creatinine generation under 
steady state conditions) on the last ICU day and compared this with predicted 
creatinine production (eG in mg/day) based on age, gender and admission weight 
[24].  
 
For males: eG = (27 - 0.173 x age) x weight 
For females: eG = (25 - 0.175 x age) x weight 
 
To validate our findings, we also performed the above measurements in ICU 
survivors without AKI. 
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Recovery of kidney function was assessed by comparing discharge Clcr and eGFR 
with baseline eGFR. For this analysis patients in whom baseline creatinine was not 
available (n=179) were omitted. Complete recovery was defined as return to 
baseline eGFR. The above measurements were performed in all AKI patients and in 
subgroups with different ICU stay: short (< 8 days), medium (8-14 days) or long  
(>14 days). Although CKD staging [26] is not strictly applicable to the early 
recovery phase of AKI, we also determined the accuracy of discharge eGFR to 
detect “potential CKD status” (GFR<60ml/min/1.73m2) defined by Clcr.  
 
Statistical analysis 
Continuous variables are expressed as median (IQR) and categorical variables as 
number and percentages. Paired continuous variables were compared with the 
Wilcoxon signed-rank test and unpaired variables with Wilcoxon/Kruskal-Wallis, 
whereas for unpaired categorical variables the Chi-square or Fisher’s exact test was 
used. Agreement (concordance) was assessed with Bland-Altman analysis for 
continuous variables and the Bowker’s test (equivalent to McNemar’s test) for 
categorical variables (proportion complete recovery). Subgroup analysis was 
performed for patients with different ICU stay. A multiple regression analysis (fit 
least square) with backward selection was performed to determine independent 
predictors of the difference between eGFR and Clcreat, including all variables that 
in univariate analysis had a p value below 0.1. Age, gender, baseline eGFR, 
malignancy, nutritional risk score (NRS), medical versus surgical admission, sepsis 
on admission, Apache II score, SOFA score, AKImax, creatinine excretion on the 
last ICU day, ICU stay and EPaNIC randomization arm were evaluated as potential 
predictors. We excluded colinearity amongst parameters and assured a (log)linear 
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relationship with outcome. Statistical analysis was performed using JMP 10 
software (SAS Institute, cary, NC). All tests were two-sided and a p value <0.05 
was considered statistically significant. 
 
Results 
------------- 
From the original study population of 4640 patients, 56 patients were excluded for 
ESRD, 15 for kidney transplantation and 9 for missing data on kidney function 
during ICU stay. AKI was diagnosed in 1296/4560 patients (28.4%). Two hundred 
twenty nine patients did not survive to ICU discharge, 77 were still on RRT at ICU 
discharge and Clcr was not available on the last day of ICU in 233 patients, leaving 
757 patients to be included in the present analysis. Baseline characteristics and 
clinical outcomes for the whole population and for patients with short, medium or 
long ICU stay are shown in table 1. Maximal AKI stage was stage 1 in 439 (58%), 
stage 2 in 137 (18%) and stage 3 in 181 (24%).   
 
At ICU discharge Clcr and eGFR significantly differed: 55.2 (34.6-81.8) and 60.6 
(40.1-97.6) ml/min/1.73m
2
 respectively (p<0.0001). Subgroup analysis showed 
significant and increasing differences in medium and long stay patients (Fig 1 A 
and Table 2). A Bland-Altman analysis (Fig 2) found an increasing bias (LOA) 
from +1.32 (-37.4/+40) in patients with short stay to +34.7 (-54.3/+123.8) 
ml/min/1.73m
2
 in patients with ICU stay >14 days. In AKI patients with medium or 
long ICU stay, the proportion of patients who had complete recovery upon 
discharge was significantly higher when assessed with eGFR compared with Clcr, 
whereas for patients with short ICU stay the reverse effect was seen. Likewise, the 
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sensitivity of discharge eGFR to detect “potential CKD status” defined by 
discharge Clcr decreased with increasing ICU stay (Table 3). 
 
Measured creatinine excretion at ICU discharge (parameter of muscle mass) was 
not significantly different from the predicted creatinine production in short-stay 
patients.  However, in medium- and long-stay patients measured creatinine 
excretion was significantly lower than predicted production with increasing 
difference with longer stay (Table 4).  
 
The 24h creatinine excretion upon discharge, baseline eGFR, ICU stay, gender and 
age (in decreasing order of importance) were independent predictors of the 
difference between eGFR and Clcr and predicted 56% of its variation. The 
parameter estimate, standard error, 95% confidence intervals, standardized beta and 
p value of the predicting variables are shown in table 5. 
 
To validate our findings we repeated the same analysis in the population of patients 
not developing AKI during ICU stay. After exclusion of 44 non-survivors and 1311 
patients with unavailable data, 1952 patients were included (baseline characteristics 
in table 1 of the electronic supplement). As in AKI patients, discharge eGFR 
significantly exceeded Clcr in medium- and long-stay patients (Table 2, Fig 1 B  
and Fig 1 of the electronic supplement). In these no-AKI patients the same 
regression model explained 72% of the variability of this difference with again 
creatinine excretion being the most powerful predictor (details in table 5). No-AKI 
patients also had a decreasing discharge creatinine excretion with longer ICU stay 
(p<0.0001) which was significantly lower than predicted creatinine production with 
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ICU stays >7 days (p=0.02 for 8-14d and p<0.0001 for >14d) (Table 4). Another 
interesting observation is a decrease of discharge creatinine compared with baseline 
in the 1499 no-AKI patients with known baseline creatinine. The difference 
increased from 0.1 (-0.01-0.2) mg/dL in short stay patients (p<0.0001) to 0.21 
(0.09-0.32) mg/dL in patients with long ICU stay (p<0.0001). 
 
 
Discussion 
------------- 
In the present study we showed that, in AKI patients with an ICU stay exceeding 7 
days, measuring kidney function at ICU discharge with eGFR significantly differed 
from the measurement with Clcr, which resulted in overestimation of renal recovery 
and underdiagnosis of “potential CKD status”. In patients not developing AKI 
during ICU stay discharge eGFR also significantly differed from Clcr. The 
discrepancy between eGFR and Clcr was most pronounced in long-stay patients 
and appears considerably explained by development of muscle wasting, gradually 
leading to a lower creatinine production/excretion than expected by anthropometric 
measures. This is supported by multiple regression analysis, in which lower 
creatinine excretion as parameter of lower muscle mass independently associated 
with a higher bias. Importantly, the inaccuracy of eGFR in long stay ICU patients is 
also applicable to creatinine, since the other components of the eGFR equation 
(age, gender and race) do not change during ICU stay. 
 
Most clinical studies on recovery from AKI are limited to independence of RRT at 
some point during follow-up after RRT-requiring AKI. Few studies have evaluated 
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the recovery from less severe forms of AKI. They use return to baseline creatinine 
[9,10], return to baseline eGFR [11,12] or absence of AKI criteria at discharge 
[27,28], all based on comparison of discharge creatinine, or the derived eGFR, with 
baseline creatinine or eGFR. The limitation of creatinine-based estimations of renal 
recovery is generally acknowledged [11,12,29] but has never before been formally 
quantified. Our study showed that the potential misclassification of renal recovery 
could be substantial in patients with prolonged ICU stay. 
 
The most significant predictor of the difference between discharge eGFR and Clcr 
was creatinine excretion, a marker of muscle mass. The impact of male gender and 
lower age can also be related to the higher muscle mass at ICU admission (more 
potential for loss). ICU-acquired weakness and muscle wasting (sarcopenia) due to 
immobilization, disuse atrophy and systemic inflammation, is a frequent problem in 
prolonged critically ill patients [20,21]. The decrease of creatinine excretion with 
prolonged ICU stay was also present in patients without AKI, where it was an even 
more powerful predictor of the bias between the two GFR measurements. Another 
indication of important muscle wasting with prolonged ICU stay is the decrease of 
serum creatinine in patients without AKI. This decrease is most pronounced with 
prolonged ICU stay which makes fluid overload a less plausible explanation. This 
finding confirms the results of a recent retrospective study in critically ill patients 
with ICU stay of more than 5 days that found significant decreases of creatinine 
during hospital stay, with discharge creatinine being significantly lower than 
baseline, except in patients with AKI stage 3  [29].   
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The reduction of muscle mass is not reflected in the surrogates that are used in the 
MDRD equation (age, race, gender), which assumes an average relationship 
between these surrogates and muscle mass and used population BSA for particular 
age and sex groups to normalize eGFR to a BSA of 1.73m
2
 [2]. The effect of 
sarcopenia on the difference between estimated and measured GFR has been 
demonstrated in patients with neuromuscular disorders [30] or liver cirrhosis [31]. 
Although sepsis has also been shown to result in decreased creatinine generation 
[32], it was not an independent predictor of the difference between eGFR and Clcr 
in our analysis. Another potential explanation for overestimation of true GFR by 
eGFR could be dilution of creatinine by positive fluid balances, which has more 
effect on eGFR than on Clcr. However, dilution is expected to have more impact in 
the early phase of ICU when AKI develops and less in the recovery phase, 
especially in patients with longer ICU stay. Absence of steady state may also 
explain the unreliability of eGFR and could underlie the lower incidence of 
complete recovery with eGFR in short-stay patients whose creatinine may be 
decreasing at the time of discharge. 
 
Our findings may have important implications for post-discharge care. In Belgium 
inclusion in a CKD program is based on the eGFR, thus excluding those patients 
with discrepancy between true GFR and eGFR resulting from sarcopenia. Our 
results also raise concern with regard to the optimal duration of follow-up after an 
episode of AKI, especially after prolonged critical illness. Some studies with longer 
follow-up time after AKI have shown improvement in kidney function [33]. Others 
have shown further deterioration [12,34], which could reflect true deterioration of 
kidney function or restoration of muscle mass after rehabilitation. Whether 
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overestimation of recovery in the early follow-up of AKI represents one of the 
reasons for AKI being a risk factor for CKD [35] remains to be investigated. The 
important discrepancy between eGFR and Clcr also includes a substantial risk for 
(eGFR-based) drug overdose in patients with prolonged ICU stay. 
 
A potential solution to the misinterpretation of renal recovery at ICU discharge may 
be the use of cystatin C or cystatin C-based GFR equations. Compared with 
creatinine cystatin C is less dependent on muscle mass [36]. Its superiority for 
detecting true GFR has indeed been demonstrated in patients with neuromuscular 
disorders [37] or chronic muscle wasting [38].  
 
The strength of our study is the large patients number and the use of a 
heterogeneous population of ICU patients. On the other hand, this analysis has 
several limitations. First, we did not use a fixed time point for the evaluation of 
recovery and we realize that ICU discharge is frequently too early. However, the 
aim of our study was to illustrate the imperfections of assessing renal recovery with 
(serum creatinine-derived) eGFR and this could only be done with simultaneous 
measurements of eGFR and Clcr, the latter not being available after ICU discharge. 
In addition, the muscle weakness and sarcopenia of prolonged critically ill patients 
can be expected to persist long after ICU discharge [39], thus hampering the 
evaluation of renal recovery with eGFR also at a later time point. 
 
Second, we did not use a golden standard (clearance of an ideal filtration marker) to 
determine “true” GFR. Both eGFR (MDRD) and Clcr have drawbacks. Common 
limitations include inaccuracies in the measurement of creatinine due to substances 
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interfering with the Jaffé method and requirement for a steady state. A stable 
kidney function can indeed not be assumed to be present in critically ill patients, 
but the instability can be reasonably expected to be less important in patients that 
are considered ready for ICU discharge and in those with longer ICU stay. Absence 
of steady state in the recovery phase will result in underestimation of GFR, which 
will be more pronounced with eGFR than with Clcr and could partially explain the 
observed difference in short-stay patients. As already stated, the MDRD equation 
has been validated in patients with stable chronic kidney disease [2], underestimates 
GFR in healthy volunteers [13,14] and is not sufficiently accurate for the estimation 
of true GFR in critically ill patients, both at low and at high levels of GFR 
[15,16,18,19]. This inaccuracy has repeatedly been emphasized with regard to the 
diagnosis of AKI but less for the evaluation of recovery. Despite these recognized 
limitations eGFR still remains widely used in the assessment of patients with AKI.  
 
The measurement of Clcr, especially when part of routine clinical practice, is 
subject to errors in urine collection. In addition, creatinine clearance may 
overestimate a low GFR because of intestinal elimination and tubular secretion 
[40], which may explain the higher discharge Clcr in short-stay patients. We 
acknowledge the limitations of the two GFR measurements but the aim of our study 
was to illustrate the inaccuracy of measuring recovery with eGFR (or serum 
creatinine) and the Clcr is expected to be closer to the golden standard than eGFR, 
especially in long-stay patients. Moreover, in these long-stay patients, the potential 
overestimation of the true GFR by measured Crcl would underestimate rather than 
overestimate the observed bias. 
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Third, we did not measure baseline Clcr or creatinine excretion and we did not 
measure body weight during ICU stay, and therefore cannot exclude that important 
muscle loss with difference between eGFR and Clcr already existed at baseline. 
However this does not invalidate the conclusion about the unreliability of eGFR or 
serum creatinine to evaluate recovery. In addition, the decrease of creatinine 
compared with baseline in long-stay patients without AKI confirms the important 
muscle wasting during ICU stay.  
 
In conclusion, in patients with prolonged ICU stay recovery of AKI is significantly 
overestimated when evaluated with eGFR. This may result in failure to detect CKD. 
By analogy, this also applies to serum creatinine, since the other determinants of 
eGFR do not change during ICU stay. These finding have important implications 
for the evaluation of recovery from AKI and for post-discharge renal care. 
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Fig 1 A. eGFR (gray boxplots) and Clcr (white boxplots) (in ml/min/1.73m
2
) at 
ICU discharge for subgroups of AKI patients with ICU stay <7d, 7-14d and >14d. 
Boxplots show median and IQR, whiskers 10
th
 and 90
th
 percentile. 
Fig 1 B. eGFR (gray boxplots) and Clcr (white boxplots) (in ml/min/1.73m
2
) at 
ICU discharge for subgroups of no-AKI patients with ICU stay <7d, 7-14d and 
>14d. Boxplots show median and IQR, whiskers 10
th
 and 90
th
 percentile. 
 
Fig 2. Bland-Altman analysis of the difference between Clcr and eGFR at ICU 
discharge A. in all AKI patients.  B. in patients with ICU stay <8d.   C. in patients 
with ICU stay between 8 and 14d. D. in patients with ICU stay >14d. The 
continuous line represents bias and the dashed lines the limits of agreement. 
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Table 1: key baseline characteristics and major clinical outcomes of AKI patients with different ICU stay. Results are presented as 
median (IQR) or n (%).* only in patients with known baseline creatinine  (n=578). NRS = nutritional risk score, eGFR = estimated GFR, 
CKD = chronic kidney disease.  
 
 
Overall 
n=757 
≤7d 
n=376 
8-14d 
n=158 
>14d 
n=223 
p 
ICU stay  (days) 8 (4-17) 4 (3-6) 10 (9-12) 25 (19-39)  
Age (years) 69.4 (58.1-76.7) 71.2 (61.6-77.6) 69.7 (58.4-77.4) 64.6 (55.2-73.5) <0.0001 
Male gender  459 (61) 217 (58) 107 (68) 135 (61) 0.09 
BMI (kg/m2) 25.7 (22.9-29.3) 25.5 (22.8-29.1) 25.3 (22.7-29.1) 26.1 (23.4-30.0) 0.28 
NRS 4 (3-4.5) 4 (3-4) 4 (3-5) 4 (3-5) 0.27 
NRS ≥5 189 (25) 73 (19) 50 (32) 66 (30) 0.002 
Diabetes  151 (20) 86 (23) 27 (17) 38 (17) 0.13 
Malignancy 184 (24) 96 (26) 36 (23) 52 (23) 0.73 
Baseline Screat  (mg/dL) 
                           [mol/L] 
0.99 (0.76-1.14) 
[87.5] 
0.98 (0.76-1.21) 
[86.6] 
1.01 (0.78-1.16) 
[89.3] 
0.94 (0.75-1.08) 
[83.1] 
0.16 
Baseline Screat not available  179 (24) 55 (15) 41 (26) 83 (38) <0.0001 
Known baseline Screat (mg/dL)*  
                           [mol/L] 
0.93 (0.69-1.23) 
[82.2] 
0.98 (0.71-1.26) 
[86.6] 
0.97 (0.70-1.28) 
[85.7] 
0.84 (0.66-1.11) 
[74.3] 
0.016 
baseline eGFR * (ml/min/1.73m2) 72.3 (50.8-102.4) 69.9 (50.0-95.8) 71.8 (48.9-111.0) 84.2 (58.6-106.1) 0.011 
CKD (eGFR <60)* 202 (35) 122 (38) 43 (37) 37 (26) 0.046 
Admission Apache II score 29  (20-36) 23 (18-32) 30 (22-37) 35  (29-40) <0.0001 
SOFA day1 9 (7-11) 8 (7-10) 9 (8-10) 10 (8-11) <0.0001 
Emergency admission  417 (55) 147 (39) 94 (59) 176 (79) <0.0001 
Surgical  714 (94) 363 (97) 143 (91) 208 (93) 0.018 
Sepsis on admission  254 (34) 76 (20) 65 (41) 113 (51) <0.0001 
Screat on admission (mg/dL)  
                           [mol/L] 
1.30 (0.93-1.83) 
[114.9] 
1.26 (0.91-1.76) 
[111.4] 
1.40 (0.95-1.97) 
[123.8] 
1.39 (0.93-2.00) 
[122.9] 
0.13 
AKImax stage     <0.0001 
Stage 1  439 (58) 281 (75) 86 (54) 72 (32)  
Stage 2  137 (18) 55 (15) 35 (22) 47 (21)  
              Stage 3 no RRT 86 (11) 35 (9) 26 (11) 25 (11)  
                               Stage 3 with RRT 95 (12) 5 (1) 11 (7) 79 (35)  
Screat at ICU discharge  (mg/dL) 
                           [mol/L] 
1.10 (0.74-1.57) 
[97.2] 
1.25 (0.89-1.72) 
[110.5] 
0.99 (0.70-1.52) 
[87.5] 
0.81 (0.57-1.35) 
[71.6] 
<0.0001 
Hospital stay (days) 27 (16-49) 18 (13-25) 28 (22-43) 54 (40-82) <0.0001 
Hospital mortality  51 (7) 14 (4) 14 (9) 23 (10) 0.003 
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Table 2: Discharge Clcr and eGFR and incidence of complete recovery by Clcr and eGFR at ICU discharge (only with known 
baseline*) for subgroups with different ICU stay.  
 
 n 
Discharge Clcreat 
median (IQR) 
Discharge eGFR 
median (IQR) 
p n*  
Baseline eGFR 
median (IQR) 
Complete recovery 
by Clcr - n (%) 
Complete recovery  
by eGFR - n (%) 
p 
AKI  757 55.2 (34.6-81.8) 60.6 (40.1-97.6) <0.0001 578 72.3 (50.8-102.4) 163 (28.2) 205 (35.5) 0.0001 
ICU stay 1-7d 376 53.4 (35.0-76.5) 51.2 (35.4-76.6) 0.86 321 69.8 (50.0-95.9) 85 (26.5) 65 (20.3) 0.003 
ICU stay 8-14d 158 53.5 (34.8-88.0) 64.0 (42.5-104.2) <0.0001 117 71.8 (48.9-111.0) 36 (30.8) 57 (48.7) 0.0002 
ICU stay >14d 223 60.8 (32.2-91.0) 84.5 (48.9-137.0) <0.0001 140 84.2 (58.6-106.0) 42 (30) 83 (59.3) <0.0001 
          
No AKI  1952 100.2 (75.4-130.1) 97.1 (74.8-127.4) 0.005      
ICU stay 1-7d 1604 98.1 (73.6-128.1) 92.2 (71.9-117.0) <0.0001      
ICU stay 8-14d 184 111.3 (85.1-144.7) 117.2 (93.6-150.2) 0.005      
ICU stay >14d 164 112.4 (89.9-144.6) 147.2 (115.5-199.4) <0.0001      
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Table 3: Ability of eGFR to detect “CKD-status” by discharge Clcr (discharge ClCr <60) 
 
 sensitivity specificity PPV NPV 
 % (95%CI) % (95%CI) % (95%CI) % (95%CI) 
ICUstay <8d (n=376) 89% (85.9-92.2) 80% (76-84) 87% (83.6-90.4) 83% (79.2-86.8) 
ICU stay 8-14d (n=158) 73% (66.1-79.9) 96% (92.9-99.1) 96% (92.7-99.1) 73% (66.1-79.9) 
ICu stay >14d (n=223) 64% (57.7-70.3) 96% (91.9-97.1) 95%(92.1-97.9) 74% (68.3-79.7) 
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Table 4: Comparison of daily creatinine excretion (in mg/day) on the last day in ICU compared 
with predicted creatinine production based on age, gender and admission weight in AKI and no 
AKI patients and in subgroups with different ICU stay.  
 
 n 
Creatinine excretion   
(mg/day)  
(median (IQR)) 
Predicted creatinine 
production (mg/day) 
(median (IQR)) 
p for 
difference 
AKI patients 757 911 (691-1217) 1065 (878-1307) <0.0001 
ICU stay 1-7d 376 1016 (783-1331) 1027 (835-1256) 0.33 
ICU stay 8-14d 158 895 (689-1158) 1042 (894-1283) <0.0001 
ICU stay >14d 223 729 (544-1040) 1132 (952-1363) <0.0001 
p for effect ICU stay  <0.0001 0.0002  
     
No AKI patients 1952 1162 (869-1510) 1106 (906-1362) <0.0001 
ICU stay 1-7d 1604 1205 (899-1537) 1094 (899-1345) <0.0001 
ICU stay 8-14d 184 1084 (807-1413) 1147 (944-1463) 0.02 
ICU stay >14d 164 885 (670-1195) 1157 (986-1470) <0.0001 
p for effect ICU stay  <0.0001 0.0007  
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Table 5: Parameter estimates of the regression analysis determining the independent predictors 
(in decreasing order of importance) of the difference between eGFR and Clcr in AKI and no AKI 
patients  
 
 
variable R
2
 estimate St Error CI 95% Standardized 
beta 
p value 
AKI patients 0.56      
Creatinine excretion  - 0.048 0.003 -0.053 / -0.043 -0.57 <0.0001 
Baseline eGFR  0.22 0.022 0.18 / 0.27 0.27 <0.0001 
ICU stay days  0.62 0.057 0.50 / 0.74 0.26 <0.0001 
Gender (M)  5.94 0.993 3.99 / 7.88 0.16 <0.0001 
Age  - 0.37 0.066 -0.50 / -0.24  -0.14 <0.0001 
       
No AKI patients 0.72      
Creatinine excretion  - 0.073 0.001 -0.075 / -0.070 -0.90 <0.0001 
Gender (M)  13.4 0.598 12.2 / 14.6 0.31 <0.0001 
Age  - 0.52 0.037 -0.59 / -0.45 -0.18 <0.0001 
ICU stay days  0.81 0.063 0.69 / 0.94 0.16 <0.0001 
Baseline eGFR  0.22 0.020 0.18 / 0.26 0.14 <0.0001 
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Fig 1 electronic supplement. Bland-Altman analysis of the difference between Clcr 
and eGFR at ICU discharge A. in all no-AKI patients.  B. in no-AKI patients with 
ICU stay <8d.   C. in no-AKI patients with ICU stay between 8 and 14d.  D. in no-
AKI patients with ICU stay >14d. The continuous line represents bias and the 
dashed lines the limits of agreement. 
 
 
 
 
  
 28 
Electronic supplementary material 
Table 1  
 
Fig 1  
 
 
